Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - hepatitis b surface antigen protein (yeast) - injection - 10 mcg/0.5 ml - hepatitis b surface antigen protein (yeast) 10 mcg/0.5 ml

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - epoprostenol - injection, powder, for solution - 0.5 mg/vial - epoprostenol 0.5 mg/vial

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - ceftazidime pentahydrate eqv ceftazidime - injection, powder, for solution - 1 g/vial - ceftazidime pentahydrate eqv ceftazidime 1 g/vial

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - human rotavirus, live, attenuated, rix 4414 strain - suspension - not less than 10⁶ ccid₅₀/dose (1.5 ml) - human rotavirus, live, attenuated, rix 4414 strain not less than 10⁶ ccid₅₀/dose (1.5 ml)

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - conjugate of streptococcus pneumoniae type 1 & haemophilus influenzae protein d; conjugate of streptococcus pneumoniae type 14 and haemophilus influenzae protein d; conjugate of streptococcus pneumoniae type 18c and tetanus toxoid; conjugate of streptococcus pneumoniae type 19f and diphtheria toxoid; conjugate of streptococcus pneumoniae type 23f and haemophilus influenzae protein d; conjugate of streptococcus pneumoniae type 4 and haemophilus influenzae protein d; conjugate of streptococcus pneumoniae type 5 and haemophilus influenzae protein d; conjugate of streptococcus pneumoniae type 6b and haemophilus influenzae protein d; conjugate of streptococcus pneumoniae type 7f and haemophilus influenzae protein d; conjugate of streptococcus pneumoniae type 9v and haemophilus influenzae protein d; diphtheria toxoid (dt) carrier protein; polysaccharide (ps); protein-d (pd) carrier protein (derived from non-typeable haemophilus influenzae); tetanus toxoid (tt) carrier protein - injection, suspension - 1 μg ps1; 1.11-1.67 μg pd/dose - conjugate of streptococcus pneumoniae type 1 & haemophilus influenzae protein d 1 μg ps1; 1.11-1.67 μg pd/dose; conjugate of streptococcus pneumoniae type 14 and haemophilus influenzae protein d 1 μg ps14; 1.00-1.82 μg pd/dose; conjugate of streptococcus pneumoniae type 18c and tetanus toxoid 3 μg ps18c; 5.45-10.00 μg tt/dose; conjugate of streptococcus pneumoniae type 19f and diphtheria toxoid 3 μg ps19f; 3.33-6.00 μg dt/dose; conjugate of streptococcus pneumoniae type 23f and haemophilus influenzae protein d 1 μg ps23f; 0.39-0.74 μg pd/dose; conjugate of streptococcus pneumoniae type 4 and haemophilus influenzae protein d 3 μg ps4; 3.33-6.67 μg pd/dose; conjugate of streptococcus pneumoniae type 5 and haemophilus influenzae protein d 1 μg ps5; 0.67-1.25 μg pd/dose; conjugate of streptococcus pneumoniae type 6b and haemophilus influenzae protein d 1 μg ps6b; 0.56-0.95 μg pd/dose; conjugate of streptococcus pneumoniae type 7f and haemophilus influenzae protein d 1 μg ps7f; 0.87-1.43 μg pd/dose; conjugate of streptococcus pneumoniae type 9v and haemophilus influenzae protein d 1 μg ps9v; 1.00-1.82 μg pd/dose; diphtheria toxoid (dt) carrier protein 3-6 μg dt/dose (total dt content); polysaccharide (ps) 16 μg/dose (total ps content); protein-d (pd) carrier protein (derived from non-typeable haemophilus influenzae) 9-16 μg pd/dose (total pd content); tetanus toxoid (tt) carrier protein 5-10 μg/dose (total tt content)

Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline consumer healthcare (ireland) limited - nicotine - medicated chewing gum - 20mg - drugs used in nicotine dependence - it is used for the treatment of tobacco dependence by relief of nicotine withdrawal symptoms including cravings during a quit attempt. permanent cessation of tobacco use is the eventual objective

Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline consumer healthcare (ireland) limited - nicotine - medicated chewing gum - 4mg - drugs used in nicotine dependence - e treatment of tobacco dependence by relief of nicotine withdrawal symptoms including cravings during a quit attempt

Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline consumer healthcare (ireland) limited - nicotine - medicated chewing gum - 2mg - drugs used in nicotine dependence - it m is used for the treatment of tobacco dependence by relief of nicotine withdrawal symptoms including cravings during a quit attempt

Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline consumer healthcare (ireland) limited - nicotine - medicated chewing gum - 4mg - drugs used in nicotine dependence - it is used for the treatment of tobacco dependence by relief of nicotine withdrawal symptoms including cravings during a quit attemp

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - influenza virus a/michigan/45/2015 (h1n1) pdm09 - like strain 15ug (a/singapore/gp1908/2015, ivr-180); influenza virus a/switzerland/8060/2017 (h3n2) like strain 15ug (a/brisbane/1/2018, nymc x-311); influenza virus b/colorado/06/2017 - like strain 15ug (b/maryland/15/2016, nymc bx-69a (victoria lineage)); influenza virus b/phuket/3073/2013 - like strain 15ug (b/phuket/3073/2013, wild type (yamagata lineage)) - suspension for injection - 0.5 ml - active: influenza virus a/michigan/45/2015 (h1n1) pdm09 - like strain 15ug (a/singapore/gp1908/2015, ivr-180) influenza virus a/switzerland/8060/2017 (h3n2) like strain 15ug (a/brisbane/1/2018, nymc x-311) influenza virus b/colorado/06/2017 - like strain 15ug (b/maryland/15/2016, nymc bx-69a (victoria lineage)) influenza virus b/phuket/3073/2013 - like strain 15ug (b/phuket/3073/2013, wild type (yamagata lineage)) excipient: d-alpha-tocopheryl acid succinate dibasic sodium phosphate dodecahydrate magnesium chloride hexahydrate monobasic potassium phosphate octoxinol polysorbate 80 potassium chloride sodium chloride water for injection - fluarix tetra is a quadrivalent vaccine indicated for active immunisation of adults and children from 6 months of age for the prevention of influenza disease caused by the influenza virus types a and b contained in the vaccine. the use of fluarix tetra should be based on official recommendations.